

**Financial Result
of 1st Quarter
Fiscal Year Ending Mar 2016**

 **KAWASUMI LABORATORIES, INC.**

August 7th 2015

1st Quarter Business Result

Consolidated

Unit: Billion YEN

	Q1 APR-JUN 2014	Q1 APR-JUN 2015	Increase / Decrease	Ratio
Net Sales	6.71	6.78	+0.07	+1.1%
Gross profit	2.25	2.33	+0.08	+3.7%
Operating income	0.24	0.37	+0.12	+50.8%
Ordinary income	0.29	0.47	+0.19	+64.3%
Net income	0.17	0.35	+0.18	+107.4%


Cost of sales to net sales (%)	66.5 %	65.6 %
-----------------------------------	--------	--------

Exchange rate	Q1 APR-JUN 2014	Q1 APR-JUN 2015
US\$	101.88	121.73
EUR	139.46	135.04
Baht	3.14	3.64

- Net Sales increased 0.07 Billion Yen by sales growth of Blood bags and Infusion Therapy products for overseas.
- Gross profit increased 0.08 Billion Yen by sales growth and cost reduction at Thai factories.
- Operating income increased 0.12 Billion Yen by SG&A expense decrease, such as consignment experimental and research expense.

Net Sales (By Segment)

(Billion YEN)



【Blood Transfusion and Endovascular】


- Increase Blood Bags
Infusion Therapy Products

【Hemodialysis and Plasmapheresis】

- Increase Blood Tubing Lines
- Decrease A.V. Fistula Needles (OEM)

Net Sales (By Region)

(Billion YEN)



【Japan】

- Increase Blood Bags
- Decrease Dialyzer Plasmapheresis

【Overseas】

- Increase Blood Bags, Dialyzer Infusion Therapy products
- Decrease A.V. Fistula Needles (OEM)

SG&A Expenses

Consolidated

Unit: Billion YEN

	Q1 APR-JUN 2014	Q1 APR-JUN 2015	Increase / Decrease
Salaries & Wages	0.74	0.74	+0.00
Logistical costs	0.25	0.24	- 0.01
R&D Expenses	0.25	0.16	- 0.09
Others	0.76	0.82	+0.06
Total	2.00	1.96	- 0.04

- R&D expenses decreased since consignment experimental and research expense decreased.

-Others increased since there was the expenditure of production relocation.



Inquiries:

Kawasumi Laboratories, Inc.
Corporate Planning
TEL : +81 (0) 3-5769-2698
Email : webmaster1@kawasumi.jp